Replimune reaches agreement with US FDA to resubmit melanoma drug application
Replimune said on Friday it it has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental skin cancer drug after the regulator twice declined to approve the therapy.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published May 29, 2026 at 8:07 AM.